Adrenocortical Carcinoma Epidemiology: Genetic History of Carney Complex a Probable Risk Factor

Published on : Nov 23, 2018

Albany, New York, November 23, 2018: Characterized by cancerous growth in adrenal glands, adrenocortical carcinoma is identified as a rare disease, affecting children and adult alike. However, lack of symptoms at early stages hampers prognosis, thus encouraging significant advancement in adrenocortical carcinoma therapeutics. A new business intelligence report titled, 'Adrenocortical Carcinoma-Market Insights, Epidemiology and Market Forecast-2027' included in the vast online data archive of Market Research Hub (MRH) identifies current market developments and their reciprocal implications on holistic growth trajectory of adrenocortical carcinoma therapeutics.

A low survival rate of approximately five years after diagnosis has encouraged leading biopharmaceutical companies as well as research institutes to integrate resources for precise R&D and clinical trials in the interest of effective adrenocortical carcinoma therapeutics development. Additionally, chances of disease recurrence remains high in adrenocortical carcinoma, often leading to fatality. Several clinical trials are at various stages of development to derive apt medication and disease management suite.

Adrenalectomy (surgery of adrenal gland), chemotherapy, and radiotherapy are accounted as potent disease management mechanisms for adrenocortical carcinoma. Over decades, mitotane has been widely accepted as a probable therapeutic tool for adrenocortical carcinoma therapeutics. However, several initiatives towards alternative treatment mechanism to arrest disease recurrence has gained significant momentum in recent years. Of late tyrosine kinase inhibitor nilotinib has been widely acknowledged to have superior cancer control potential as opposed to mitotane. Based on this new study, leading pharmaceutical companies are expected to leverage potential R&D activities to incur new drugs for adrenocortical carcinoma management. 

This elaborate research report on adrenocortical carcinoma discusses crucial parameters encompassing triggers of incidence, progression, prognosis, and disease control mechanism. The report sheds considerable light on current, historical, as well as forecast values of adrenocortical carcinoma epidemiology. The report details crucial market attributes such as disease definition, and eventual therapeutic trends. The report entails veritable insights on market dynamics, drivers, trends, and opportunities that influence growth trajectory in adrenocortical carcinoma therapeutics market. This section of the report also gauges pipeline portfolio of leading companies for adrenocortical carcinoma therapeutics. The report identifies therapeutics assessment and therapeutics development as distinguishing factors in adrenocortical carcinoma therapeutics market, besides offering a preview of unmet patient needs, imminent launch of pipeline drugs, competitive substitutes, as well as alternative therapy.

Further, the report also includes detailed analytical review of country-wide reach of adrenocortical carcinoma therapeutics market, emphasizing on epidemiology progression. Key countries studies in the report comprise EU countries such as Germany, France, Italy, Spain, and United Kingdom. United States, and Japan.  

Request a Sample with TOC in a PDF format :

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top